Harnessing the Power
of Selectivity in
Complement Therapeutics
Dianthus Therapeutics is advancing next generation complement therapeutics to deliver transformative medicines for patients with rare diseases. Our mission is to develop best-in-class, potent and selective antibodies of validated and emerging complement targets to transform the lives of people living with autoimmune diseases.
We envision the full potential of complement therapeutics lies within the power of selectivity. Our antibodies are modified with half-life extension technology and uniquely equipped with a high selectivity for active complement proteins, resulting in the potential for effective therapeutics with reduced dose levels and frequency to improve the lives of patients.
We are designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies.
DISCOVERY | PRECLINICAL | PHASE I/II PHASE I/II | PIVOTAL STUDIES PIVOTAL STUDIES | |||||
---|---|---|---|---|---|---|---|---|
DNTH103 – ACTIVE C1s SELECTIVE ANTIBODY | ||||||||
DNTH200 | ||||||||
DNTH300 |
At Dianthus, we are a multidisciplinary team of biotech entrepreneurs and scientists united by the commitment to harness the power of selectivity in complement therapeutics to create transformative medicines for people living with rare autoimmune diseases.
At Dianthus, we are a multidisciplinary team of biotech entrepreneurs and scientists united by the commitment to harness the power of selectivity in complement therapeutics to create transformative medicines for people living with rare autoimmune diseases.
- Leadership
- Board Of Directors
- Investors
- Leadership
- Board Of Directors
- Investors
We believe in growth and persistence with change. With offices in Waltham, MA and New York City, NY, Dianthus is currently looking to strengthen our team with visionary, entrepreneurial scientists and experts motivated to make a lasting impact in the lives of patients through novel complement therapeutics. Grow with us.